Lunai Bioworks Court & Legal Update
Lunai Bioworks has requested that Nasdaq immediately suspend trading of its common stock (LNAI) due to evidence of irregular trading activity uncovered during discovery in its pending litigation against Seven Points Capital LLC. The company alleges substantial short selling, locate deficiencies, and concentrated failures to deliver that may indicate the market for its shares is not fair or orderly. Nasdaq has not yet made a decision on the request, and the underlying litigation in the U.S. District Court for the District of Delaware remains ongoing.
- Counterparty
- Seven Points Capital LLC